RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Clinical trials for RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy targets tough lymphoma
Disease control Recruiting nowThis study tests a combination of two treatments—zanubrutinib (a targeted drug) and lisocabtagene maraleucel (a CAR T-cell therapy)—for people with Richter's syndrome, an aggressive lymphoma that has returned or not responded to prior treatment. About 24 participants will receive…
Matched conditions: RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Aseel Alsouqi • Aim: Disease control
Last updated May 17, 2026 08:04 UTC
-
Triple-Drug attack shows promise against rare blood cancer
Disease control Recruiting nowThis study tests a combination of three drugs—lisocabtagene maraleucel (a personalized cell therapy), nivolumab (an immunotherapy), and ibrutinib (a targeted pill)—in 20 adults with Richter's transformation, an aggressive form of leukemia. The goal is to see if this triple therap…
Matched conditions: RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 08:02 UTC
-
New drug combo targets aggressive blood cancer in early trial
Disease control Recruiting nowThis early-phase study tests whether combining two drugs—zanubrutinib and odronextamab—is safe and effective for people with Richter's transformation, an aggressive lymphoma that can develop from chronic lymphocytic leukemia. The trial enrolls 23 adults whose cancer has come back…
Matched conditions: RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New drug duo shows promise for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study tests whether combining two targeted drugs—loncastuximab tesirine and mosunetuzumab—can shrink or eliminate tumors in people with diffuse large B-cell lymphoma that has returned or not responded to prior treatment. About 36 adults will receive the drug combination, and…
Matched conditions: RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
Engineered immune cells take on tough blood cancers in new trial
Disease control Recruiting nowThis early-phase trial tests a new type of CAR T-cell therapy for people with certain blood cancers (like lymphoma, leukemia) that have returned or not responded to standard treatments. The therapy uses a patient's own immune cells, modified in a lab to target three cancer marker…
Matched conditions: RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
Engineered immune cells take on tough blood cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called MC10029, which uses a patient's own immune cells (T cells) that are modified in a lab to attack cancer cells. It is for people with certain types of blood cancers (like lymphoma or leukemia) that have returned or stopped respond…
Matched conditions: RECURRENT TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 04, 2026 16:23 UTC